Search

Your search keyword '"Bernabucci, Veronica"' showing total 2 results
Start Over Author "Bernabucci, Veronica" Topic boceprevir
2 results on '"Bernabucci, Veronica"'

1. The role played by gender in viral hepatitis.

Author

Bernabucci, Veronica and Villa, Erica

Subjects
*VIRAL hepatitis, *GENDER, *ESTROGEN, *MENOPAUSE, *HEPATITIS C virus
Abstract

Although not a classical target for estrogens, the liver is a target for their action and is sensitive to their deprivation. The occurrence of menopause is accompanied by a chain of events depending on the progressive estrogen deprivation that eventually leads to a shift from a low inflammatory to a high inflammatory state. This has a series of well-known consequences in many different organs and tissues (bone, heart, brain, body fat etc.) among which the liver is particularly interesting. The consequences are extremely evident in HCV-positive women in whom HCV infection and menopause cooperate to induce higher necro-inflammatory features, increased hepatic steatosis and eventually faster progression of fibrosis. In addition, menopause is the strongest negative factor for sustained viral response (SVR) in HCV-positive females, especially HCV genotype 1 (in whom menopause was the only independent factor for failure of antiviral therapy). This suggests that HCV-positive women should be treated early during fertile age to obtain maximal response to antiviral therapy. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

2. Chronic hepatitis C retreatment with boceprevir in menopausal women.

Author

Bernabucci, Veronica and Turco, Laura

Subjects
*CHRONIC hepatitis C, *HEPATITIS C treatment, *CHRONIC disease treatment, *BOCEPREVIR, *THERAPEUTIC use of protease inhibitors, *MENOPAUSE, *THERAPEUTICS
Abstract

Menopausal women who are infected with hepatitis C virus (HCV) represent a very difficult-to-treat cohort of patients. Menopause represents, in fact, a special time in a woman's life in which there are hormonal changes that affect the state of health. In particular, the decline of ovarian function determines an estrogen deprivation that is associated with rapid progression of hepatic fibrosis. There is, therefore, a loss of estrogen protection against inflammation, which is followed by an increase in the levels of proinflammatory cytokines: this determines a low sensitivity to antiviral therapy. In fact, a greater resistance to antiviral therapy in women with chronic hepatitis C genotype 1 was observed after the onset of menopause, with a rate of sustained virological response less than 40%. The positive results of many studies that added boceprevir to standard antiviral therapy suggests that triple therapy in a cohort of difficult-to-treat menopausal women who are HCV-positive genotype 1 with previous failure to standard therapy will result in a high percentage of complete early virological response in these patients. Therefore, there are now new opportunities for treatment of HCV-positive genotype 1 menopausal women. [ABSTRACT FROM AUTHOR]

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results